DOSSIER #083READ: 4 MIN
SECTOR: Synthetic Bio
Biomanufacturing Supply Chokepoints
Why raw peptide precursors, fermentation capacity and export licensing concentrate risk for cell and gene therapy developers.
SCENARIO VARIABLE: SUPPLIER CONCENTRATIONHIGH CONCENTRATION
// REF: RU-SYNTH-083Access Brief →